FCGR2A and cancer: mFc provides several advantageous features compared to dimeric Fc such as (i) the smaller size that can enable better tissue penetration particularly essential for use in cancer therapy, (ii) no effector functions since for most therapeutic proteins direct cytotoxicity is not involved in their mode of action and in many cases should be avoided (Dimitrov, 2012), and (iii) the unique FcγR-binding profile leading to improved therapeutic efficacy in some clinical applications (Ying et al., 2014).